PMC:7228307 / 25198-25351 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"451","span":{"begin":138,"end":144},"obj":"Disease"}],"attributes":[{"id":"A451","pred":"tao:has_database_id","subj":"451","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T253","span":{"begin":39,"end":46},"obj":"Body_part"},{"id":"T254","span":{"begin":42,"end":46},"obj":"Body_part"}],"attributes":[{"id":"A253","pred":"fma_id","subj":"T253","obj":"http://purl.org/sig/ont/fma/fma63147"},{"id":"A254","pred":"fma_id","subj":"T254","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T45","span":{"begin":47,"end":51},"obj":"Disease"},{"id":"T46","span":{"begin":96,"end":99},"obj":"Disease"},{"id":"T47","span":{"begin":138,"end":144},"obj":"Disease"}],"attributes":[{"id":"A45","pred":"mondo_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/MONDO_0008734"},{"id":"A46","pred":"mondo_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/MONDO_0016702"},{"id":"A47","pred":"mondo_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T482","span":{"begin":39,"end":46},"obj":"http://purl.obolibrary.org/obo/CL_0000623"}],"text":"These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T129","span":{"begin":6,"end":14},"obj":"Chemical"}],"attributes":[{"id":"A129","pred":"chebi_id","subj":"T129","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"}],"text":"These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T149","span":{"begin":15,"end":24},"obj":"http://purl.obolibrary.org/obo/BFO_0000034"},{"id":"T150","span":{"begin":42,"end":46},"obj":"http://purl.obolibrary.org/obo/CL_0000000"}],"text":"These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"451","span":{"begin":138,"end":144},"obj":"Disease"}],"attributes":[{"id":"A451","pred":"pubann:denotes","subj":"451","obj":"MESH:D009369"}],"text":"These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T146","span":{"begin":0,"end":153},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T252","span":{"begin":39,"end":46},"obj":"Body_part"},{"id":"T253","span":{"begin":42,"end":46},"obj":"Body_part"}],"attributes":[{"id":"A252","pred":"fma_id","subj":"T252","obj":"http://purl.org/sig/ont/fma/fma63147"},{"id":"A253","pred":"fma_id","subj":"T253","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy."}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T66","span":{"begin":47,"end":51},"obj":"http://purl.obolibrary.org/obo/GO_0001788"}],"text":"These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T17","span":{"begin":138,"end":144},"obj":"Disease"}],"attributes":[{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy."}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T8","span":{"begin":138,"end":144},"obj":"Phenotype"}],"attributes":[{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy."}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T66","span":{"begin":47,"end":51},"obj":"http://purl.obolibrary.org/obo/GO_0001788"}],"text":"These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T66","span":{"begin":47,"end":51},"obj":"http://purl.obolibrary.org/obo/GO_0001788"}],"text":"These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy."}

{"project":"LitCovid-sentences","denotations":[{"id":"T146","span":{"begin":0,"end":153},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T8","span":{"begin":138,"end":144},"obj":"Phenotype"}],"attributes":[{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy."}